Pfizer inks strategic collaboration with Syapse to analyze RWD, advance outcomes research

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/utah778)
(Image: Getty/utah778)

Related tags: Pfizer, Syapse, Real-world data, Real-world evidence, Outcomes research, Oncology

Syapse today announces a strategic collaboration with Pfizer through which it will generate insights from de-identified real-world data and advance oncology outcomes research.

Syapse’s insights platform, data sharing network, and industry partnerships help advance the delivery of precision cancer care, according to the company, which today announced a strategic collaboration with Pfizer.

“With its health system partners, Syapse has built a network of real-world data that offers a unique view of modern cancer care, including how molecular tests are used to diagnose and treat patients. A real-world database, if you will,”​ a Syapse spokesperson told us.

The company’s partners include Advocate Aurora Health, CommonSpirit Health, Henry Ford Health System, Providence St. Joseph Health, and Seoul National University Hospital. Syapse also earlier this year announced a collaboration with Amgen​, and in 2018 initiated a partnership with Medidata​ to develop a new suite of solutions addressing precision medicine challenges.

Per its strategic collaboration with Pfizer, the companies will initially focus on molecular testing and precision oncology therapy choices and outcomes of patients in the US health care system.

“Syapse will provide Pfizer with the ability to analyze this de-identified real-world data and work with them to collaboratively advance outcomes research projects,”​ the spokesperson added.

The deal with Syapse is Pfizer's latest through which the pharma company aims to advance oncology through the use of real-world data. Pfizer in April of this year announced a partnership with Concerto HealthAI​ to accelerate actionable insights for Pfizer’s precision oncology work on investigational and commercialized therapeutics for the treatment of solid tumors and hematologic malignancies.

Related news

Show more

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

Related suppliers

Follow us

Products

View more

Webinars